TY  - JOUR
AU  - Dinkel, Hendrik
AU  - Materna, Linus
AU  - Stelmach, Ramona
AU  - Zschäbitz, Stefanie
AU  - Neuberger, Stephanie
AU  - Aydogdu, Can D
AU  - Casuscelli, Jozefina
AU  - Egenolf, Timo
AU  - Silberg, Matteo
AU  - Steinestel, Julie
AU  - Strauss, Arne
AU  - Kirchhoff, Florian
AU  - Ahrens, Marit
AU  - Paffenholz, Pia
AU  - Cathomas, Richard
AU  - Özdemir, Berna C
AU  - Gossler, Christopher
AU  - Ivanyi, Philipp
AU  - Rehlinghaus, Marc
AU  - Hilser, Thomas
AU  - Grünwald, Viktor
AU  - Schlack, Katrin
TI  - Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS group.
JO  - International journal of cancer
VL  - nn
SN  - 0020-7136
CY  - Bognor Regis
PB  - Wiley-Liss
M1  - DKFZ-2025-02666
SP  - nn
PY  - 2025
N1  - epub
AB  - Ipilimumab and nivolumab are recommended as first-line therapy for patients with metastatic or advanced renal cell carcinoma (aRCC) and International Metastatic RCC Database Consortium (IMDC) intermediate or poor risk. We retrospectively evaluated efficacy and safety in a multi-center real-world cohort with 356 patients initiating ipilimumab and nivolumab from 17 centers in Germany and Switzerland. Median age was 64 years, most patients were male (69.1
KW  - immunotherapy (Other)
KW  - ipilimumab (Other)
KW  - nivolumab (Other)
KW  - real‐world (Other)
KW  - renal cell carcinoma (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41317031
DO  - DOI:10.1002/ijc.70267
UR  - https://inrepo02.dkfz.de/record/306673
ER  -